Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations
Background: Increased expression of type I interferon (IFN)-regulated genes has been described in blood and tissue cells from patients with systemic lupus erythematosus (SLE) and other rheumatic disorders. Only isolated studies have examined the type I IFN gene expression in antiphosholipid syndrome...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00487/full |
id |
doaj-c4b0bf4c9ddd48a7951767b4e6cac079 |
---|---|
record_format |
Article |
spelling |
doaj-c4b0bf4c9ddd48a7951767b4e6cac0792020-11-24T21:16:17ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-03-011010.3389/fimmu.2019.00487430220Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory AssociationsEleni PalliEvrydiki KravvaritiMaria G. TektonidouBackground: Increased expression of type I interferon (IFN)-regulated genes has been described in blood and tissue cells from patients with systemic lupus erythematosus (SLE) and other rheumatic disorders. Only isolated studies have examined the type I IFN gene expression in antiphosholipid syndrome (APS), while efforts to evaluate associations with APS-related factors are scarce.Objective: Our aim was to investigate the type I IFN signature in patients with primary APS (PAPS), SLE/APS, and SLE in comparison with healthy controls, and to evaluate associations with disease-related characteristics.Methods: We measured the type I IFN score, derived from relative expressions of three IFN-inducible genes (MX-1, IFIT-1, and IFI-44) in peripheral blood mononuclear cells from 55 patients with PAPS, 34 with SLE/APS, 48 with SLE, and 28 controls. In patients with PAPS, we performed multivariate regression to examine associations of type I IFN score with their clinical, laboratory and treatment characteristics.Results: Type I IFN score was increased in all patient groups vs. controls (p = 0.028, p = 0.027, p = 0.028 for PAPS, SLE/APS, and SLE, respectively). IFI-44 had the most pronounced expression. In patients with PAPS, multivariate linear regression revealed positive associations of type I IFN score with female gender (b-coefficient = 0.49; 95% CI 0.04, 0.94; p = 0.034) and IgG or IgM anti-β2GPI antibodies (b-coefficient = 0.53; 95% CI 0.10, 0.96; p = 0.017), and negative associations with age (b-coefficient = −0.02/year; 95% CI −0.04, −0.01; p = 0.027) and hydroxychloroquine use (b-coefficient = −0.51; 95% CI-0.96, −0.06; p = 0.027).Conclusion: Type I IFN score is increased in PAPS and correlated positively with anti-β2GPI antibodies and negatively with hydroxychloroquine use.https://www.frontiersin.org/article/10.3389/fimmu.2019.00487/fullantiphospholipid syndromesystemic lupus erythematosustype I Interferon signaturetype I Interferon scoreantiphospholipid antibodiesanti-b2-glycoprotein I antibodies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eleni Palli Evrydiki Kravvariti Maria G. Tektonidou |
spellingShingle |
Eleni Palli Evrydiki Kravvariti Maria G. Tektonidou Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations Frontiers in Immunology antiphospholipid syndrome systemic lupus erythematosus type I Interferon signature type I Interferon score antiphospholipid antibodies anti-b2-glycoprotein I antibodies |
author_facet |
Eleni Palli Evrydiki Kravvariti Maria G. Tektonidou |
author_sort |
Eleni Palli |
title |
Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations |
title_short |
Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations |
title_full |
Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations |
title_fullStr |
Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations |
title_full_unstemmed |
Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations |
title_sort |
type i interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2019-03-01 |
description |
Background: Increased expression of type I interferon (IFN)-regulated genes has been described in blood and tissue cells from patients with systemic lupus erythematosus (SLE) and other rheumatic disorders. Only isolated studies have examined the type I IFN gene expression in antiphosholipid syndrome (APS), while efforts to evaluate associations with APS-related factors are scarce.Objective: Our aim was to investigate the type I IFN signature in patients with primary APS (PAPS), SLE/APS, and SLE in comparison with healthy controls, and to evaluate associations with disease-related characteristics.Methods: We measured the type I IFN score, derived from relative expressions of three IFN-inducible genes (MX-1, IFIT-1, and IFI-44) in peripheral blood mononuclear cells from 55 patients with PAPS, 34 with SLE/APS, 48 with SLE, and 28 controls. In patients with PAPS, we performed multivariate regression to examine associations of type I IFN score with their clinical, laboratory and treatment characteristics.Results: Type I IFN score was increased in all patient groups vs. controls (p = 0.028, p = 0.027, p = 0.028 for PAPS, SLE/APS, and SLE, respectively). IFI-44 had the most pronounced expression. In patients with PAPS, multivariate linear regression revealed positive associations of type I IFN score with female gender (b-coefficient = 0.49; 95% CI 0.04, 0.94; p = 0.034) and IgG or IgM anti-β2GPI antibodies (b-coefficient = 0.53; 95% CI 0.10, 0.96; p = 0.017), and negative associations with age (b-coefficient = −0.02/year; 95% CI −0.04, −0.01; p = 0.027) and hydroxychloroquine use (b-coefficient = −0.51; 95% CI-0.96, −0.06; p = 0.027).Conclusion: Type I IFN score is increased in PAPS and correlated positively with anti-β2GPI antibodies and negatively with hydroxychloroquine use. |
topic |
antiphospholipid syndrome systemic lupus erythematosus type I Interferon signature type I Interferon score antiphospholipid antibodies anti-b2-glycoprotein I antibodies |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2019.00487/full |
work_keys_str_mv |
AT elenipalli typeiinterferonsignatureinprimaryantiphospholipidsyndromeclinicalandlaboratoryassociations AT evrydikikravvariti typeiinterferonsignatureinprimaryantiphospholipidsyndromeclinicalandlaboratoryassociations AT mariagtektonidou typeiinterferonsignatureinprimaryantiphospholipidsyndromeclinicalandlaboratoryassociations |
_version_ |
1726016293770887168 |